Last €218.11 EUR
Change Today -1.48 / -0.67%
Volume 4.1K
As of 12:20 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-genusschein (RHO5) Snapshot

Open
€218.95
Previous Close
€219.59
Day High
€220.40
Day Low
€217.98
52 Week High
02/28/14 - €226.65
52 Week Low
08/1/13 - €183.66
Market Cap
188.3B
Average Volume 10 Days
4.2K
EPS TTM
--
Shares Outstanding
702.6M
EX-Date
03/6/14
P/E TM
--
Dividend
€7.78
Dividend Yield
2.93%
Current Stock Chart for ROCHE HOLDING AG-GENUSSCHEIN (RHO5)

roche holding ag-genusschein (RHO5) Related Bloomberg News

View More Bloomberg News

roche holding ag-genusschein (RHO5) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate that is in clinical development for treating non-small-cell lung cancer. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holding ag-genusschein (RHO5) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holding ag-genusschein (RHO5) Key Developments

AstraZeneca Enters into Cancer Diagnostic Test Collaborations with Roche and QIAGEN

AstraZeneca and Roche will be collaborating on developing a plasma-based companion diagnostic test to support AstraZeneca's drug candidate AZD9291, which is undergoing clinical development for non-small-cell lung cancer (NSCLC). Separately, AstraZeneca will also be partnering with QIAGEN (Netherlands) in developing a non-invasive diagnostic test that would help identify NSCLC patients that would be suitable for treatment with AstraZeneca's Iressa (gefitinib).

Advanced Biological Laboratories and Roche Diagnostics International Renew and Extend Their Collaboration Agreement to Promote Their Next-Generation Sequencing, Genotyping and Drug Resistance Products

Advanced Biological Laboratories announced the renewal of a non-exclusive collaboration agreement with Roche Diagnostics International for Europe, Middle East, Africa (EMEA) and Latin America (LATAM) territories. This collaboration agreement is intended to develop a strategy to promote ABL products especially its next-generation sequencing platform DeepChek(R) together with Roche's next generation sequencing systems (GS Junior and GS FLX+ Sequencing Systems) for molecular virology. The principal objectives of the collaboration are to provide its mutual customers with integrated sequencing and analysis systems delivering the required quality, sensitivity and meaningful genotyping and drug resistance reporting for personal healthcare. The collaboration has been extended from HIV to viral hepatitis B and C.

Roche Holding AG Reports Earnings Results for the First Half of 2014; Provides Earnings Guidance for the Year 2014

Roche Holding AG reported earnings results for the first half of 2014. For the period, the company's net profit drop 7% compared with a year ago, weighed down by a strong Swiss franc and charges from one of its diagnostic units. Sales were CHF 22.974 billion, down 1% from CHF 23.295 billion from a year ago. Core operating profit was CHF 9,410 million against CHF 9,488 million a year ago. Operating free cash flow was CHF 7,869 million against CHF 7,445 million a year ago. Net income was CHF 5,641 million against CHF 6,047 million a year ago. Diluted core earnings per share were CHF 7.57 against CHF 7.58 a year ago. For the full year 2014, the company expects low- to mid-single digit growth in Group sales at constant exchange rates. Core EPS is targeted to grow ahead of sales.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHO5:GR €218.11 EUR -1.48

RHO5 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $25.64 USD +0.19
Gilead Sciences Inc $93.79 USD +0.80
Johnson & Johnson $102.30 USD +0.34
Novartis AG SFr.80.35 CHF +0.35
Sanofi €76.89 EUR +0.07
View Industry Companies
 

Industry Analysis

RHO5

Industry Average

Valuation RHO5 Industry Range
Price/Earnings 20.9x
Price/Sales 4.5x
Price/Book 12.7x
Price/Cash Flow 17.0x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-GENUSSCHEIN, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.